Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Sales and Divestitures (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $387925.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures changed N/A to $387925.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $387925.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $387925.0 for FY2025, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $387925.0 at Whitehawk Therapeutics, roughly flat from $387925.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $387925.0 in Q3 2025, with the low at $63000.0 in Q1 2025.